SLCO1B3 and acute lymphoblastic leukemia: This is aligned with the results reported by Banach et al. [24], who found no significant influence of these SLCO1B3 polymorphisms on MTX efficacy in a cohort of 151 pediatric patients with acute lymphoblastic leukemia (ALL).